3677 related articles for article (PubMed ID: 34383735)
41. Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months - United States, April 2023.
Moulia DL; Wallace M; Roper LE; Godfrey M; Rosenblum HG; Link-Gelles R; Britton A; Daley MF; Meyer S; Fleming-Dutra KE; Oliver SE; Twentyman E
MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(24):657-662. PubMed ID: 37319020
[TBL] [Abstract][Full Text] [Related]
42. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.
Sessa M; Kragholm K; Hviid A; Andersen M
Expert Opin Drug Saf; 2021 Nov; 20(11):1451-1453. PubMed ID: 34264151
[No Abstract] [Full Text] [Related]
43. The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020.
Dooling K; Marin M; Wallace M; McClung N; Chamberland M; Lee GM; Talbot HK; Romero JR; Bell BP; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jan; 69(5152):1657-1660. PubMed ID: 33382671
[TBL] [Abstract][Full Text] [Related]
44. The safety profile of COVID-19 vaccinations in the United States.
Singh A; Khillan R; Mishra Y; Khurana S
Am J Infect Control; 2022 Jan; 50(1):15-19. PubMed ID: 34699960
[TBL] [Abstract][Full Text] [Related]
45. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ;
MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832
[TBL] [Abstract][Full Text] [Related]
46. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
47. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt JG; Thompson D; Su JR; Myers TR; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(28):899-903. PubMed ID: 35834416
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
49. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
50. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022.
Twentyman E; Wallace M; Roper LE; Anderson TC; Rubis AB; Fleming-Dutra KE; Hall E; Hsu J; Rosenblum HG; Godfrey M; Archer WR; Moulia DL; Daniel L; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(31):988-992. PubMed ID: 35925807
[TBL] [Abstract][Full Text] [Related]
51. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
[TBL] [Abstract][Full Text] [Related]
52. Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years - United States, March 29, 2022-July 10, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt J; Blanc PG; Su JR; Hugueley B; Parker C; Myers TR; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(30):971-976. PubMed ID: 35900925
[TBL] [Abstract][Full Text] [Related]
53. Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2023.
Regan JJ; Moulia DL; Link-Gelles R; Godfrey M; Mak J; Najdowski M; Rosenblum HG; Shah MM; Twentyman E; Meyer S; Peacock G; Thornburg N; Havers FP; Saydah S; Brooks O; Talbot HK; Lee GM; Bell BP; Mahon BE; Daley MF; Fleming-Dutra KE; Wallace M
MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(42):1140-1146. PubMed ID: 37856366
[TBL] [Abstract][Full Text] [Related]
54. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021.
Oliver SE; Gargano JW; Scobie H; Wallace M; Hadler SC; Leung J; Blain AE; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; MacNeil J; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(9):329-332. PubMed ID: 33661860
[No Abstract] [Full Text] [Related]
55. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021.
Hause AM; Gee J; Johnson T; Jazwa A; Marquez P; Miller E; Su J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):685-688. PubMed ID: 33956781
[TBL] [Abstract][Full Text] [Related]
56. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
57. A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.
Yih WK; Daley MF; Duffy J; Fireman B; McClure D; Nelson J; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
Vaccine; 2023 Jan; 41(3):826-835. PubMed ID: 36535825
[TBL] [Abstract][Full Text] [Related]
58. Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program - United States, December 14, 2020-January 14, 2021.
Painter EM; Ussery EN; Patel A; Hughes MM; Zell ER; Moulia DL; Scharf LG; Lynch M; Ritchey MD; Toblin RL; Murthy BP; Harris LQ; Wasley A; Rose DA; Cohn A; Messonnier NE
MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(5):174-177. PubMed ID: 33539333
[TBL] [Abstract][Full Text] [Related]
59. Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination.
Formeister EJ; Wu MJ; Chari DA; Meek R; Rauch SD; Remenschneider AK; Quesnel AM; de Venecia R; Lee DJ; Chien W; Stewart CM; Galaiya D; Kozin ED; Sun DQ
JAMA Otolaryngol Head Neck Surg; 2022 Apr; 148(4):307-315. PubMed ID: 35201274
[TBL] [Abstract][Full Text] [Related]
60. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
